Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

takeda pharma a/s, denmark - ixazomib citrate - capsule, hard - 2.3 mg

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

takeda pharmaceutical company limited. - ixazomib citrate - faint red capsule, major axis: approx. 14.3 mm, minor axis: 5.3 mm

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

takeda pharmaceutical company limited. - ixazomib citrate - light gray capsule, major axis: approx. 14.3 mm, minor axis: 5.3 mm

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

takeda pharmaceutical company limited. - ixazomib citrate - pale orange capsule, major axis: approx. 15.9 mm, minor axis: 5.8 mm

European Union - English - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - elotuzumab - multiple myeloma - antineoplastic agents - empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy (see sections 4.2 and 5.1).

Israel - English - Ministry of Health

bristol, myers squibb (israel) limited, israel - elotuzumab - powder for concentrate for solution for infusion - elotuzumab 300 mg/vial - elotuzumab - empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.empliciti is indicated in combination with pomalidomide and dexamethasone for the treatment ofadult patients with relapsed and refractory multiple myeloma who have received at least two priortherapies, including lenalidomide and a proteasome inhibitor, and have demonstrated diseaseprogression on the last therapy.

Israel - English - Ministry of Health

bristol, myers squibb (israel) limited, israel - elotuzumab - powder for concentrate for solution for infusion - elotuzumab 400 mg/vial - elotuzumab - empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.empliciti is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on the last therapy.